1. Home
  2. GOSS vs ORIC Comparison

GOSS vs ORIC Comparison

Compare GOSS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.51

Market Cap

796.2M

Sector

Health Care

ML Signal

HOLD

Logo Oric Pharmaceuticals Inc.

ORIC

Oric Pharmaceuticals Inc.

HOLD

Current Price

$9.13

Market Cap

783.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
ORIC
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
796.2M
783.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
GOSS
ORIC
Price
$2.51
$9.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
13
Target Price
$8.60
$19.73
AVG Volume (30 Days)
5.3M
1.4M
Earning Date
11-05-2025
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,051,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$3.90
52 Week High
$3.87
$14.93

Technical Indicators

Market Signals
Indicator
GOSS
ORIC
Relative Strength Index (RSI) 34.97 49.21
Support Level $2.35 $7.84
Resistance Level $3.87 $8.92
Average True Range (ATR) 0.27 0.40
MACD -0.12 0.19
Stochastic Oscillator 12.32 89.96

Price Performance

Historical Comparison
GOSS
ORIC

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Share on Social Networks: